Skip to main content
Singapore Clinical Research Institute will NEVER ask you to transfer money or disclose bank details over a call.

If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg (opens in new tab).

Singapore Clinical Research Institute (SCRI)

AHCC06 2nd Interim Analysis 2014

The AHCC06 (SIRveNIB) trial's second Interim Analysis confirmed good trial conduct, solid data, and strong safety outcomes. Read on for details from the Data Safety and Monitoring Board's review.

Last updated on 17 March 2026
Marina Bay Sands hotel with three towers and rooftop skypark beside dome-shaped conservatories in Singapore.

The AHCC06 (SIRveNIB) trial had its second Interim Analysis in Singapore on 27 October 2014. The objective of the second analysis is to continue review the progress, safety and efficacy of the trial, and to make recommendations on the future direction and conduct of the trial. 

We are pleased to share that the Data Safety and Monitoring Board (DSMB) found the overall conduct of the trial is good, protocol has been well executed and the data is solid and acceptable.

A DSMB is an independent group of experts who monitor safety of patients and treatment efficacy data while a clinical trial is ongoing. The board comprised of Dr Thomas Leung (Chairman), Prof David Machin and Prof Bruno Sangro.

In Photo: Ms Sandra Hsing (CRA), Ms Cindy Seow (CRA), Ms Paula Yip (CRA), Dr Leung (DSMB Chair), Prof Pierce Chow (Protocol Chair), Prof Machin (DSMB Member), Prof Sangro (DSMB Member), Mr Xia Yu (Project Manager), Ms Isabelle Lee (Head, Project Management), Dr Mihir Gandhi (Trial Statistician) and Mr Liew Wei Ming (CRA) at the meeting.

Ten people pose around a large oval conference table with a projection screen displaying a presentation behind them.